Macroeconomic Context and Operating Environment

Bangladesh's macroeconomic background establishes severe operating headwinds for import-dependent manufacturing sectors, including domestic formulation pharmaceuticals. Economic growth has moderated, with GDP growth recorded at 4.14 percent per annum according to the World Bank World Development Indicators for FY2023, while the Bangladesh Bureau of Statistics (BBS) provisional figure stood at 6.0 percent for FY23. Headline price pressures have remained elevated, marked by an annual average Consumer Price Index (CPI) inflation rate of 10.47 percent according to the World Bank for 2024, alongside a BBS reading of 9.7 percent in December 2024. This sustained inflation erodes consumer purchasing power, compresses household health expenditures, and escalates manufacturing overheads across industrial establishments.

External sector accounts display persistent structural deficits. Total merchandise imports reached USD 63.7 billion for FY2023-24 on a cost, insurance, and freight basis, outstripping adjusted merchandise exports of USD 44.5 billion over the same fiscal period. The resulting trade deficit has been partially mitigated by remittance inflows, which totaled USD 23.91 billion in FY2023-24, representing an expansion of 10.66 percent year-on-year. Official foreign exchange reserves calculated under the International Monetary Fund Balance of Payments and International Investment Position Manual sixth edition (IMF BPM6) stood at USD 31.07 billion as reported by Bangladesh Bank in December 2024. Simultaneously, the exchange rate reached 122.75 BDT per USD at the Bangladesh Bank mid-rate at the end of December 2024. This currency depreciation has directly elevated the local currency cost of imported active pharmaceutical ingredients (APIs), packaging materials, excipients, and capital machinery.

Fiscal balances constrain the state's capacity to extend broad subsidies or fiscal stimulus to industrial enterprises. The fiscal deficit stood at 4.7 percent of GDP under the revised budget for FY2023-24 from the Ministry of Finance, while public debt reached 40.1 percent of GDP according to World Bank and IMF assessments for 2024. Compounding the real-economy pressures, the domestic financial system faces acute balance-sheet stress. Following the Bangladesh Bank Basel III reclassification in late 2025, the non-performing loan ratio reached 35.73 percent. This impairment of bank capital severely constrains industrial credit intermediation, restricts access to trade financing, elevates the cost of working-capital borrowing, and hampers letter-of-credit operations for domestic manufacturing enterprises.

Market Structure and Industrial Concentration

Data compiled by the Bangladesh Association of Pharmaceutical Industries (BAPI) delineates a market characterized by an extreme structural divide between top-tier manufacturers and the rest of the sector. Bangladesh possesses 258 pharmaceutical manufacturers. However, industrial scale and market control are concentrated within a narrow corporate tier. The top 20 companies account for 94 percent of total production, leaving the remaining 238 companies to share only 6 percent of production.

This structural concentration generates bifurcated operational dynamics across the domestic supply chain:

1. Top-tier manufacturers (the top 20 firms) possess the scale economies, modern production infrastructure, regulatory compliance capabilities, and working-capital buffers necessary to secure international accreditations, negotiate bulk procurement of raw materials, and maintain nationwide distribution footprints.
2. Bottom-tier manufacturers (the remaining 238 firms) operate in a highly precarious environment. Deprived of scale economies and producing only 6 percent of industry output, these fringe producers face prohibitive unit overheads, minimal pricing leverage, and limited liquidity reserves. Under conditions of imported input inflation, these entities confront existential balance-sheet stress, frequently operating at sub-optimal capacity utilization.

This asymmetry has direct ramifications for competition policy and domestic medicine supply security. While the leading producers preserve operational viability through sheer volume and broader product portfolios, the heavy dependence of the market on a concentrated cohort of 20 firms exposes the domestic healthcare supply chain to aggregate risk if macroeconomic shocks, trade disruptions, or regulatory interventions impair the balance sheets of these dominant market participants.

Financial Stress, Pricing Distortions, and Revenue Contraction

The convergence of domestic retail price controls and imported input inflation has induced widespread operational contraction throughout the pharmaceutical landscape. According to IQVIA data cited by industry stakeholders, 64 of the top 100 pharmaceutical companies in Bangladesh recorded negative growth in 2025. This negative trajectory among nearly two-thirds of the country's prominent manufacturing entities highlights an unviable cost-price squeeze.

The primary driver of this financial strain is the structural divergence between uncontrolled import costs and rigid retail price caps:

• Input Cost Pressures: Domestic medicine manufacturing remains structurally dependent on imported active ingredients, specialized reagents, and processing components. The depreciation of the currency to 122.75 BDT per USD, coupled with broader average CPI inflation of 10.47 percent, has driven up manufacturing, utility, and labor costs.
• Rigid Price Controls: Even as input inflation accelerated, medicine price ceilings remained frozen. Because manufacturers were legally prohibited from adjusting ex-factory and maximum retail prices in line with prevailing domestic currency costs, operating margins collapsed.

The contraction experienced by 64 of the top 100 manufacturers indicates that operating losses are no longer confined to sub-scale producers within the bottom 238 firms. Instead, margin compression has directly affected core tier-two and upper-tier manufacturers. In response, firms have deferred capital expenditures, delayed modernization programs, trimmed product lines, and curbed inventory accumulation of essential formulations. Such defensive corporate strategies elevate the medium-term risk of localized product shortages and compromise supply stability across both public and private procurement channels.

Regulatory and Legal Developments in Drug Pricing

The sector's operating strains have been exacerbated by administrative and legal instability surrounding the statutory mechanism for medicine price determination. In 2026, the Cabinet formally scrapped the interim government's "Essential Drugs List 2026" and "Drug Price Determination Method 2026."

The legal rationale for invalidating these regulatory instruments centered on administrative non-compliance with governing legislation. Under the Drugs and Cosmetics Act 2023, the executive is subject to a statutory requirement to consult the National Drug Advisory Council prior to altering drug schedules and pricing methodologies. Because this statutory consultation requirement had been bypassed during the drafting and promulgation of the 2026 frameworks, the Cabinet nullified both the updated essential drug schedule and the revised price determination formula.

As a direct consequence of this invalidation, the government reverted to the 1994 pricing mechanism pending the legal formulation and gazetting of an updated list. This administrative reversal maintains an obsolete regulatory framework:

• Antiquated Pricing Parameters: The 1994 pricing regime was designed under radically different macroeconomic parameters, cost structures, and therapeutic realities. Its cost-build formulas do not capture contemporary manufacturing processes, current utility overheads, or the elevated exchange rate environment (122.75 BDT per USD).
• Policy Uncertainty: Reverting to a framework over three decades old creates acute uncertainty for corporate planning, capital allocation, and regulatory compliance. Pharmaceutical manufacturers cannot formulate multi-year investment or production plans in the absence of a legally sound, predictable pricing formula that reflects input realities while safeguarding consumer access.
• Institutional Procedural Integrity: The nullification underscores that structural policy reforms cannot bypass the institutional mechanisms established under primary legislation. Sustainable market regulation requires strict adherence to statutory bodies, such as the National Drug Advisory Council mandated under the Drugs and Cosmetics Act 2023, to insulate state decisions from legal vulnerability and abrupt administrative reversals.

Trade Integration and Export Trajectories

Despite acute domestic market headwinds, the export footprint of Bangladesh's pharmaceutical industry has demonstrated modest nominal expansion alongside sustained geographical diversification. Pharmaceutical exports reached USD 213 million in fiscal year 2024–2025, expanding by 4 percent from USD 205 million recorded in FY 2023–2024.

Concurrently, the global presence of domestic formulations has widened significantly over the medium term. Export destinations expanded from 140 countries to 166 countries over a seven-year period. This geographic expansion across 166 destination markets reflects expanding regulatory registrations, compliance upgrades among top-tier manufacturers, and sustained commercial efforts to penetrate semi-regulated and regulated markets abroad.

Export revenue growth provides an essential source of direct foreign exchange earnings for manufacturing conglomerates. At an aggregate scale of USD 213 million, however, pharmaceutical exports remain modest relative to total national merchandise exports of USD 44.5 billion. While serving as an important proof of manufacturing quality and technical competence, current export earnings are insufficient to insulate the broader sector from domestic market disruptions, given that the vast bulk of installed capacity remains dedicated to meeting local consumption requirements.

Financial System Linkages and Capital Constraints

The sector's operational resilience is tightly interlinked with stability in the domestic banking sector. The banking system's non-performing loan ratio climbed to 35.73 percent following the Bangladesh Bank Basel III reclassification in late 2025. This magnitude of balance-sheet impairment within financial institutions produces broad systemic consequences for industrial capital access:

• Working Capital Constraints: Pharmaceutical formulation involves long cash conversion cycles, driven by lengthy lead times for API procurement, manufacturing batch releases, laboratory quality controls, and retail distribution credit. With more than a third of banking sector loans classified as non-performing, commercial banks have tightened credit underwriting, constrained working-capital credit lines, and raised collateral requirements.
• Foreign Exchange and Letter-of-Credit Bottlenecks: Although aggregate foreign exchange reserves stood at USD 31.07 billion at the end of 2024 under the IMF BPM6 accounting standard, the combination of high bank non-performing loans and trade deficits (USD 63.7 billion in imports versus USD 44.5 billion in exports) impairs the capacity of commercial banks to confirm letters of credit promptly. Delays in trade credit confirmation disrupt API inventory pipelines, raising inventory holding costs for manufacturers.
• Asymmetric Capital Allocation: Under constrained credit conditions, domestic banks allocate scarce financing primarily to the top 20 manufacturers due to their collateral backing and production dominance (94 percent of output). The remaining 238 manufacturers, which produce only 6 percent of output, face severe credit exclusion, accelerating financial distress and potential capacity exits among sub-scale enterprises.

Risk Matrix and Structural Headwinds

The medium-term outlook for the pharmaceutical sector over the remainder of 2026 is defined by several compounding operational and institutional risks:

1. Regulatory Gridlock and Margin Erosion: Operating under the reinstated 1994 pricing mechanism prevents timely pass-through of import inflation. If statutory consultations under the Drugs and Cosmetics Act 2023 remain unresolved, continued negative growth across major manufacturers (such as the 64 top-100 companies affected in 2025) will jeopardize supply stability for essential medicines.
2. Macroeconomic and Currency Volatility: With CPI inflation at 10.47 percent and an exchange rate of 122.75 BDT per USD, further exchange-rate adjustments will immediately amplify API acquisition costs. In the absence of flexible pricing mechanisms, margins will experience further structural degradation.
3. Credit Intermediation Failure: With the banking sector's non-performing loan ratio at 35.73 percent, impaired banking institutions cannot supply the long-term debt financing required for capital upgrades, bioequivalence studies, and compliance modernization. This credit barrier limits the sector's ability to diversify beyond simple generic formulations into higher-value therapeutics.
4. Industrial Bifurcation: The concentration of 94 percent of production within 20 companies leaves the market vulnerable to firm-specific shocks. Should any leading conglomerate encounter corporate or liquidity distress, the remaining 238 manufacturers lack the production capacity (currently 6 percent of total output) to offset resultant domestic supply deficits.

Strategic Levers and Policy Priorities

Restoring operational stability and financial sustainability across the pharmaceutical sector requires sequenced policy measures targeting regulatory coherence, market transparent pricing, and financial stabilization:

• Reconstitute Statutory Regulatory Processes: The Ministry of Health and Family Welfare must immediately convene the National Drug Advisory Council as mandated by the Drugs and Cosmetics Act 2023. Formal stakeholder consultations must be completed to establish a legally sound replacement for the invalidated Essential Drugs List 2026 and Drug Price Determination Method 2026. Bypassing statutory consultation invites legal challenges and prolongs reliance on the outdated 1994 formula.
• Design an Inflation-Indexed Pricing Mechanism: Rather than enforcing rigid price freezes that have forced 64 of the top 100 manufacturers into negative growth, regulatory authorities must construct an objective, transparent pricing formula. This mechanism should integrate movements in the exchange rate (benchmarked against the market rate of 122.75 BDT per USD) and prevailing CPI inflation (10.47 percent), allowing predictable, periodic adjustments while protecting affordability for core essential drugs.
• Address Industrial Concentration and Supply Resilience: Industrial policy must address the structural divide between the top 20 producers and the remaining 238 firms. Targeted programs should encourage consolidation, mergers, or contract-manufacturing partnerships, enabling sub-scale firms to upgrade their quality systems and absorb overhead costs more effectively.
• Targeted Trade Financing Facilities: To insulate medicine manufacturing from the high non-performing loan environment (35.73 percent), Bangladesh Bank should ensure designated trade-credit and letter-of-credit support mechanisms for essential active pharmaceutical ingredients, utilizing the stability afforded by foreign exchange reserves (USD 31.07 billion under IMF BPM6) to prevent disruptions in essential formulation manufacturing.
• Foster Export Market Expansion: Capitalizing on pharmaceutical exports reaching USD 213 million across 166 destination countries requires supporting manufacturers with regulatory compliance infrastructure, mutual recognition agreements, and trade diplomacy to expand market access beyond basic generic formulations.

Sober, coordinated execution across these regulatory, macroeconomic, and industrial policy domains will be necessary to resolve current financial distress and preserve domestic supply integrity.